2017 INTERIM REPORT

TABLE OF CONTENTS

This Interim Report contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond MDxHealth's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this Interim Report to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation.

I. INTERIM MANAGEMENT REPORT

Highlights

Key non-audited financials, as of June 30, 2017

Amounts as at and for the six months ended

USD thousands	June 30, 2017	June 30, 2016
Total revenues	24,260	12,945
Total operating expenses	18,709	15,985
EBITDA Profit/(Loss)	1,433	-6,699
Operating profit (EBIT)	552	-7,528
Net Profit/(Loss)	538	-7,618
Earnings per share, basic ($)	0.01	-0.17
Number of outstanding shares	49,949,408	45,269,633
Cash and cash equivalents	30,509	20,114

Revenue and income

Total revenue for the first six months ended June 30, 2017, increased by 87% to $24.3 million, compared to $12.9 million a year earlier. Revenue included the sale of the Company's patents directed towards colorectal cancer to Exact Sciences. Excluding revenue from Exact Sciences for both periods, total revenue increased by approximately 10% to $12 million during the first half of 2017. ConfirmMDx accounted for 93% of such revenue in the first half of 2017, compared to 98% in the first half of 2016. Test volumes for SelectMDx grew tenfold year-on-year and account for 35% of total volumes, while the revenue contribution in this early stage of payor adoption in the US amounts to 5%. Revenue recognized on the sales of ConfirmMDx and SelectMDx represented nearly 50% of total gross billings, a level comparable to 2016. A marginal increase in the revenue recognition rate for ConfirmMDx was offset by the lower rate applicable to the fast-growing test volumes of SelectMDx.

The gross profit margin on products and services remained level with last year at nearly 60% with improvements for ConfirmMDx being offset by the lower margins on SelectMDx given the initial lower levels of revenue recognition.

Operating expenses for the six months ended June 30, 2017 amounted to $18.7 million, up $2.7 million compared to the first half of 2016. The increase partly resulted from the accelerated expansion of the sales force in the US to address the mounting market opportunity for its robust portfolio of molecular diagnostic tests for urology. Also, reflected in the increase, is the impact for the full 6 months of investments made during 2016 such as the build-out of the European operations including commercial and laboratory staff.

Operating profit and EBITDA improved by $8.1 million to $0.6 million and $1.4 million, respectively, largely attributable to the royalty buy out by Exact Sciences.

Cash position

Cash and cash equivalents stood at $30.5 million at June 30, 2017, compared to $30.8 million at December 31, 2016. The gross proceeds from the sale of patents to Exact Sciences of $15 million were offset by an operational cash burn of $13.4 million, the non-recurring payment of royalties and milestones of $0.7 million and investments in tangible and intangible assets of $2.7 million. Cash collections from ConfirmMDx and SelectMDx amounted to $10.8 million, 31% more than a year earlier. The unique ConfirmMDx CPT code, effective January 2018, is expected to further streamline the Company's reimbursement efforts and significantly reduce collection periods.

Justification to continue using the accounting rules on the basis of going concern

Despite cumulated losses, the Board has decided to continue to apply the accounting rules on the basis of going concern. This decision is justified by (i) the success of the technology of the Company in various cancer applications and scientific publications, (ii) continued interest in the Company's technology, (iii) the continued industry growth in the field of molecular diagnostics and personalized medicine, and (iv) the fact that sufficient cash is available to support further development of the Company's products over the next 12 months period in function of the current business plan. Considering the situation, the Board of Directors believes that there is enough cash to sustain the current projects of the Company at least until the date of the annual general shareholders' meeting scheduled for May 2018.

Principal risks related to the business activities

The principal risks related to the MDxHealth's business activities have been outlined in the 2016 Annual Report, which is available on the internet at www.mdxhealth.com/investors/financials.htm.

Declaration of responsible persons

The Board of Directors of MDxHealth SA, represented by all its members, declares that, as far as it is aware, the financial statements in this Interim Report, made up according to the applicable standards for financial statements, give a true and fair view of the equity, financial position and the results of the company and its consolidated companies. The Board of Directors of MDxHealth SA, represented by all its members, further declares that this Interim Report gives a true and fair view on the information that has to be contained herein. The condensed consolidated interim financial statements have been prepared in accordance with International Accounting Standard (IAS) 34 (Interim Financial Reporting) as adopted by the European Union.

II. INTERIM CONDENSED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
MDxHealth SA
For the six months ended 30 June 2017

1. CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

In thousands of USD

	Note	as at June 30, 2017	as at Dec 31, 2016
ASSETS			
Goodwill		1,145	1,145
Intangible assets	**4**	14,555	12,829
Property, plant and equipment		2,343	2,259
Non-current assets		**18,043**	**16,233**
Inventories		1,388	1,479
Trade receivables	**5**	15,791	18,498
Prepaid expenses and other current assets		930	640
Cash and cash equivalents	**5**	30,509	30,871
Current assets		**48,618**	**51,488**
Total assets		**66,661**	**67,721**
EQUITY AND LIABILITIES			
Share capital		45,946	45,853
Issuance premium		101,239	101,105
Accumulated profit/(loss)		(98,800)	(85,626)
Result of the year		538	(13,174)
Share-based compensation		5,634	5,269
Translation reserves		613	(686)
Total equity		**55,170**	**52,741**
Deferred tax liabilities		673	729
Long term liabilities	**5**	661	1,550
Loans and borrowings		233	108
Non-current liabilities		**1,567**	**2,387**
Loans and borrowings		307	430
Trade payables	**5**	6,595	7,546
Other current liabilities	**5**	2,139	3,535
Short-term liabilities	**5/7**	883	1,082
Current liabilities		**9,924**	**12,593**
Total equity and liabilities		**66,661**	**67,721**

2. CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF PROFIT AND LOSS AND OTHER COMPREHENSIVE INCOME

In thousands of USD (except per share amounts)

Continuing Operations	Note	Jan-June 2017	Jan-June 2016
Product and service income	3	12,004	10,938
Patent income	3	7,000	0
Royalties	3	5,256	1,930
Government grant income		0	77
Revenues		**24,260**	**12,945**
Cost of goods and services sold		4,999	4,488
Gross Profit		**19,261**	**8,457**
Research and development expenses		832	1,057
Selling, general and administrative expenses		17,903	15,121
Other operating income		26	193
Other operating expenses		0	0
Total operating charges		**18,709**	**15,985**
Operating profit/(loss) (EBIT)		**552**	**(7,528)**
Financial income		16	3
Financial expenses		86	149
Profit/(loss) before income taxes		**482**	**(7,674)**
Income taxes		(56)	(56)
Profit/(loss) for the period		**538**	**(7,618)**
Profit/(loss) for the period[1]		**538**	**(7,618)**
Other comprehensive income			
Items that will be reclassified to profit or loss:			
Exchange differences arising on translation of foreign operations		1,299	224
Total comprehensive income for the period (net of tax) [1]		**1,837**	**(7,394)**
Basic earnings per share in USD		0.01	(0.17)
Diluted earnings per share in USD		0.01	(0.17)
Shares used in computing per share amount – basic (number outstanding shares)		49,949,408	45,269,633

[1] All amounts are attributable to equity holders of MDxHealth SA since there are no minority interests

3. CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS

In thousands of USD

	Jan-June 2017	Jan-June, 2016
CASH FLOWS FROM OPERATING ACTIVITIES		
Operating profit/(loss)	552	(7,528)
Depreciation, amortization and impairment results	881	829
Share-based compensation	365	353
Interest paid	(10)	(8)
Income taxes	0	0
Change in inventories	91	153
(Increase)/decrease in accounts receivable [(1)]	2,417	(3,068)
Increase/(decrease) in accounts payable [(2)]	(2,266)	(455)
Total adjustments	1,478	(2,196)
Net cash provided by/(used in) operating activities	**2,030**	**(9,724)**
CASH FLOWS FROM INVESTING ACTIVITIES		
Interest received	4	0
Other financial profit/(loss)	(126)	(138)
Acquisition of property, plant and equipment	(451)	(344)
Acquisition of intangible assets	(2,231)	(1,613)
Net cash provided by/(used in) investing activities	**(2,804)**	**(2,095)**
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from bank loan	296	36
Payments on contingent consideration	(1,105)	
Payments on loans and borrowings	(297)	(218)
Proceeds from issuance of shares (net of issue costs)	227	220
Net cash provided by/(used in) financing activities	**(879)**	**38**
Net increase/(decrease) in cash and cash equivalents	**(1,653)**	**(11,781)**
Cash and cash equivalents at beginning of year	**30,871**	**31,680**
Effect of exchange rates	1,291	215
Cash and cash equivalents at end of period	**30,509**	**20,114**

(1) = long term grants receivable + short term grants receivable + trade receivables + prepaid expenses & other current assets
(2) = long term grants payable + trade payables + other current liabilities

MDxHealth

4. CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY

	Number of shares	Share capital	Issuance Premium	Retained earnings	Share-based compensation	Translation reserves	Total Equity
Balance at 1 January 2016	**45,153,633**	**42,791**	**83,118**	**-85,626**	**4,701**	**-722**	**44,262**
Loss for the period				-7,618			**-7,618**
Other comprehensive income						224	**224**
Total comprehensive income for the period				**-7,618**		**224**	**-7,394**
Issuance of shares	116,000	103	117				**220**
Share-based compensation					353		**353**
Balance at 30 June 2016	**45,269,633**	**42,894**	**83,235**	**-93,244**	**5,054**	**-498**	**37,441**

	Number of shares	Share capital	Issuance Premium	Retained earnings	Share-based compensation	Translation reserves	Total Equity
Balance at 1 January 2017	**49,845,595**	**45,853**	**101,105**	**-98,800**	**5,269**	**-686**	**52,741**
Profit for the period				538			**538**
Other comprehensive income						1,299	**1,299**
Total comprehensive income for the period				**538**		**1,299**	**1,837**
Issuance of shares	103,813	93	134				**227**
Share-based compensation					365		**365**
Balance at 30 June 2017	**49,949,408**	**45,946**	**101,239**	**-98,262**	**5,634**	**613**	**55,170**

5. EXPLANATORY NOTES

Accounting policies

1. Basis of preparation

The condensed consolidated interim financial statements have been prepared in accordance with International Accounting Standard (IAS) 34 - Interim Financial Reporting, as adopted by the European Union.

These interim consolidated financial statements do not include all the information required for full annual financial statements and should be read in conjunction with the consolidated financial statements of the Company as at and for the year ended 31 December 2016. The reporting and functional currency of the Company is the U.S. Dollar.

The preparation of the condensed consolidated interim financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated interim financial statements and the reported amounts of revenue and expenses during the reporting period. If in the future such estimates and assumptions, which are based on management's best estimates and judgment, deviate from the actual circumstances, the original estimates and assumptions will be modified and the effects of the revisions will be reflected in the period in which the circumstances change.

Notwithstanding the losses sustained during the Company's existence, the Company has close this reporting period with $30,509 thousand under Cash & cash equivalents. Despite the profit realized during the first six months of 2017, the company expects to continue to incur losses during the last 6 months of the financial year 2017. Based on the current cash availability, the board of directors however believes that the future research programs and the Company activities can be continued for more than one year. Consequently, the accounts have been prepared on a going concern basis.

2. Significant accounting policies

The Company applies the International Financial Reporting Standards (IFRS) as adopted by the European Union. The same accounting policies, presentation and methods of computation have been followed in these condensed financial statements as were applied in the preparation of the Group's financial statements for the year ended 31 December 2016, except for the impact of the adoption of the Standards and Interpretations described below.

New Standards, Interpretations and Amendments adopted by the Group

During the current financial year, the Group has adopted all the new and revised Standards and Interpretations issued by the International Accounting Standards Board (IASB) and the International Financial Reporting Interpretations Committee (IFRIC) of the IASB, that are relevant to its operations and effective for the accounting year starting on 1 January 2017. The Group has not applied any new IFRS requirements that are not yet effective as per 30 June 2017.

Standards and Interpretations issued but not yet effective in the current period

The Group elected not to early adopt the following new Standards, Interpretations and Amendments, which have been issued but not yet endorsed by the European Union as per June 30, 2017.

- Annual Improvements to IFRSs 2014-2016 Cycle
- IFRS 2 Share-based Payment — Amendments to clarify the classification and measurement of share-based payment transactions
- IFRS 9 Financial Instruments — Classification and Measurement

- IFRS 15 Revenue from Contracts with Customers
- IFRS 15 Revenue from Contracts with Customers – Clarifications
- IFRS 16 Leases
- IAS 7 Cash flow statement — Amendments as result of the Disclosure initiative

None of the other new standards, interpretations and amendments, which are effective for periods beginning after 1 July 2017 and which have not been adopted early, are expected to have a material effect on the Group's future financial statements, except for the application of IFRS 15 and IFRS 16 which have been discussed in the consolidated financial statements of the Company as at and for the year ended 31 December 2016.

The preparation of the interim condensed financial statements in compliance with IAS 34 requires the use of certain critical accounting estimates. It also requires the Company's management to exercise judgment in applying the Company's accounting policies.

There were no changes in the areas where significant judgments and estimates have been made.

3. Segment information

The Company does distinguish different geographical operating segments since at this time the revenues are generated from clinical laboratory service testing, or the out-licensing of the Company's patented DNA methylation platform and biomarkers in both United States of America and Europe.

Total geographical external revenue of customers and geographical non-current assets is shown in the following graph.



The Company has recognized net revenue amounting to $12.1 million for the sale of MDxHealth patents directed toward colorectal cancer to Exact Sciences. The transaction included a one-time fee $7.0 million to acquire the ownership of the patent rights and $8 million one-time fee with respect to a royalty buy-out for its continuing use of a biomarker. The Company already recognized $2.9 million royalties in 2016 which were unpaid at 31 December 2016. The transaction has no effects in future financial statements.

4. Capitalisation of internal developed projects

Generally, the Company considers that the regulatory and clinical risks inherent to the development of its products preclude it from capitalizing development costs. Development costs for products that will be sold can be capitalized as an intangible asset. It is dependent upon management's judgment that a technological and economic basis exists and that a project has reached a feasibility, clinical acceptance and subsequence commercialization milestone that supports the likelihood of revenue generation. Also the costs must be identifiable to meet the requirements for capitalization. Similar to the product development costs related to improving capacity, quality, and reagent costs, the study costs for clinical utility, health economic studies, decision impact studies, and comparative effectiveness are all mandatory requirements under the MolDx program to qualify for clinical use and reimbursement contracts with government and third party payor organizations. These studies are an integrated part of the of the product development. Without these studies the Company has no viable product and the product will be labeled for research or investigational use only.

During 2016, the Company capitalized internally generated development costs related to the enhancement of the ConfirmMDx for Prostate assay, but also for the development & improvement of SelectMDx and AssureMDx amounted to $5,322 thousand.

In the course of 2017, the Company did significant progress on the enhancement of the ConfirmMDx for Prostate assay as well as development and improvement of SelectMDx and AssureMDx and considers these expenses eligible for capitalization. Furthermore significant costs were capitalized with respect to the implementation of a new operating system. A total of $2,232 is capitalized under Intangible assets.

5. Financial instruments and fair value

The carrying value and fair value of the financial instruments for 30 June 2017 and 31 December 2016 can be presented as follows:

Financial assets	**30 June 2017**	**31 December 2016**	**Hierarchy**
Trade receivables	15,791	18,498	
Cash and cash equivalents	30,509	30,871	
Total financial assets	**46,300**	**49,369**	
Financial liabilities			
Financial liabilities at fair value:			
Contingent consideration payable	1,544	2,632	Level 3
Subtotal financial liabilities at fair value	**1,544**	**2,632**	
Financial liabilities at amortized cost:			
Loans and borrowings	540	538	
Trade payables	6,595	7,546	
Other liabilities	2,139	3,535	
Subtotal financial liabilities at amortized cost	**9,274**	**11,619**	
Total financial liabilities	**10,818**	**14,251**	

The carrying value of the financial instruments has been determined on the basis of the following methods and assumptions :

- The carrying value of the cash and cash equivalents, the trade receivables, the trade payables and the other liabilities approximate their fair value due to their short term character;
- Loans and borrowings are evaluated based on their interest rates and maturity date. Their fair value approximates their carrying value.
- The fair value of contingent consideration payable is based on an estimated outcome of the conditional purchase price/contingent payments arising from contractual obligations. This is initially recognized as part of the purchase price and subsequently fair valued with changes recorded through profit and loss. The Company used a discount rate of 9.30%. If expected

cash flows were 10% higher or lower, the fair value would remain the same value since it does not impact the milestone payments.

Fair value hierarchy
The Company uses the following hierarchy for determining and disclosing the fair value of financial instruments by valuation technique:

- Level 1 : quoted prices in active markets for identical assets and liabilities;
- Level 2 : other techniques for which all inputs which have a significant effect on the recorded fair value are observable, either directly or indirectly; and
- Level 3 : techniques which use inputs that have a significant effect on the recorded fair value that are not based on observable market data.

No financial assets or financial liabilities have been reclassified between the valuation categories during the period.

6. Changes in composition

During the course of the first six months of 2017, the structure of the Group did not change compared to the situation at the end of 2016.

7. Contingent consideration

The Company signed a sale and purchase agreement on September 18, 2015 to acquire all shares and voting interests of NovioGendix, an entity incorporated in The Netherlands.

Under the terms of the agreement, the Company is committed to pay up to $3.3 million subject to meeting certain milestones, be payable in six milestone payments. During the first half of 2017 the Company paid $1.1 million.

The contingent consideration is valued at every reporting date and the change in fair value only relates to the time value of money, all other assumptions remained unchanged compared to 31 December 2016. This contingent liability has been evaluated to a fair-value of $1.5 million at the end of June 2017 and $ 833 thousand is included in the current liabilities and $ 661 thousand is included in non-current liabilitiesof the balance sheet.

8. Related party transactions

Transactions between MDxHealth SA, MDxHealth BV and MDxHealth Inc., which are related parties, have been eliminated in consolidation and are not disclosed in this note. The intercompany services between all the MDxHealth group entities relate to R&D and administrative services carried out by the subsidiary companies on behalf of the parent company and to administrative services carried out by the parent company for the subsidiaries.

Beside remuneration, warrants and bonus there are no other transactions to key personnel than these already mentioned in the 2016 financial statements. For the first half of 2017, the total remuneration for key management and Directorsis $0.9 million, and they were granted a total of 460.000warrants.

There were no other related party transactions.

9. Warrant plans

During the first half of 2017, the Company granted a total of 664.000 warrants to employees, consultants and directors of the Company and its subsidiaries. The warrants have been granted free of charge. Each warrant entitles its holders to subscribe to one common share of the Company at a

subscription price determined by the board of directors, within the limits decided upon at the occasion of their issuance.

The fair value of each warrant is estimated on the date of grant using the Black-Scholes methodology with the following assumptions:

- The dividend return is estimated by reference to the historical dividend payment of the Group. Currently, this is estimated to be zero as no dividends have been paid since inception.
- The expected volatility was determined using the average volatility of the stock over the last two years at the date of grant.
- Risk-free interest rate is based on the interest rate applicable for the 10Y Belgian government bond at the grant date

The model inputs for warrants granted during the period ended 30 June 2017 included:

Grant date	**1-1-2017**	**1-3-2017**	**1-4-2017**	**11-4-2017**	**1-6-2017**	**20-6-2017**	**27-6-2017**
Exercise price	4,56	5,26	5,41	5,35	5,01	4,97	4,98
Expiry date	31-3-2024	31-3-2024	31-3-2024	31-3-2024	31-3-2024	31-3-2027	31-3-2027
Share price at grant date	4,87	5,45	5,30	5,28	4,92	5,03	4,93
Expected price volatility	54%	53%	52%	52%	52%	52%	51%
Risk-free interest rate	0,73%	0,68%	0,81%	0,75%	0,59%	0,59%	0,66%

The fair value of the granted warrant is estimated at $365k following the underlying assumptions of the model.

10. Subsequent events

On July 3, MDxHealth announced that results from an independent urology survey identify lack of knowledge on the new generation biomarker tests for Prostate Cancer. Survey data were presented on June 28th at the fifth Global Congress on Prostate Cancer in Lisbon, Portugal.

In July, MDxHealth announced the commercial launch of its AssureMDx(TM) for Bladder Cancer test in the United States as a laboratory developed test (LDT). Testing will be conducted at the Company's state-of-the-art CAP and CLIA accredited laboratory facilities in Irvine, California. AssureMDx is a non-invasive, urine-based test, combining methylation and mutation biomarkers, to assess the risk of bladder cancer for patients diagnosed with hematuria. AssureMDx has been validated to improve upon the standard of care, helping rule out the risk of bladder cancer with a negative predictive value (NPV) of 99%.2 The high NPV led study investigators to report that the test could potentially spare as many as 77% of hematuria patients from undergoing a cystoscopy.2 Furthermore, the test's 93% sensitivity and 85% specificity can help doctors identify patients at increased risk for bladder cancer, who may benefit from cystoscopy.

The Company also announced on July 10 that it has signed a commercial agreement with IPS Genomix for the distribution of its SelectMDx® for Prostate Cancer test in the Middle East. With their expert teams covering Lebanon, Egypt, United Arab Emirates, Saudi Arabia, Oman, Bahrain, Qatar, and Jordan, IPS Genomix is ideally positioned to reach the estimated 1 million men across the region with an elevated PSA, who would be potential candidates for SelectMDx. Under the terms of the agreement, IPS Genomix will handle distribution and reimbursement for SelectMDx within the Middle East, while MDxHealth will perform the SelectMDx testing service in its state-of-the-art ISO certified clinical diagnostic laboratory in Nijmegen, The Netherlands. IPS Genomix will reimburse MDxHealth for all testing services performed.

On July 31, the Company announced that MVZ Dr. Stein & Kollegen medical laboratory has signed an agreement to become the first German laboratory to offer the SelectMDx for Prostate Cancer test.

Under the terms of the agreement, MVZ Dr. Stein & Kollegen medical laboratory in Mönchengladbach Germany, one of the laboratories within the Limbach Gruppe SE, will perform SelectMDx service testing. To offer this service through their network, the laboratory will purchase SelectMDx CE-marked IVD kits from MDxHealth.

The Company also announced on August 8 that it has signed a health care services agreement with Southern California Permanente Medical Group to assess the performance of the ConfirmMDx® for Prostate Cancer test. Southern California Permanente Medical Group* is a physician-led organization that serves the 4.4 million members of Kaiser Permanente Southern California.

On August 7, MDxHealth announced the appointment of Paul Marr as Executive Vice President of Sales for North America in conjunction with the expansion of its US sales force to 50 representatives.

Expansion of the US sales force to 50 representatives has been timed to address the Company's mounting market opportunity for its robust portfolio of molecular diagnostic tests for urology, including its lead product ConfirmMDx®, its new SelectMDx(TM) liquid biopsy test, and its recently launched liquid biopsy bladder cancer test, AssureMDx(TM).

On August 10, MDxHealth announced that results from a study published in The Prostate further validated ConfirmMDx® for Prostate Cancer and showed that the test can provide treating urologists with deeper insights into a patient's risk for aggressive prostate cancer.

6. STATUTORY AUDITOR'S REPORT TO THE BOARD OF DIRECTORS OF MDXHEALTH SA ON THE REVIEW OF THE CONSOLIDATED INTERIM FINANCIAL INFORMATION FOR THE SIX-MONTH PERIOD ENDED 30 JUNE 2017

Introduction

We have reviewed the accompanying interim consolidated statement of financial position of MDxHealth SA as of 30 June 2017 and the related interim consolidated statements of comprehensive income, cash flows and changes in equity for the six-month period then ended, as well as the explanatory notes. The Board of Directors is responsible for the preparation and presentation of this consolidated interim financial information in accordance with IAS 34 "Interim Financial Reporting", as adopted by the European Union. Our responsibility is to express a conclusion on this consolidated interim financial information based on our review.

Scope of review

We conducted our review in accordance with International Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying consolidated interim financial information is not prepared, in all material respects, in accordance with IAS 34 "Interim Financial Reporting", as adopted by the European Union.

Zaventem, 30 August 2017

BDO Bedrijfsrevisoren Burg. Ven. CBVA / BDO Réviseurs d'Entreprises Soc. Civ. SCRL
Statutory auditor
Represented by Gert Claes

III. CORPORATE INFORMATION

Registered office

MDxHealth SA has the legal form of a public limited liability company (société anonyme - SA / naamloze vennootschap - NV) organized and existing under the laws of Belgium. The company's registered office is located at CAP Business Center, Rue d'Abhooz 31, B-4040 Herstal, Belgium.

The company is registered with the Registry of Legal Persons (registre des personnes morales - RPM / rechtspersonenregister – RPR) under company number RPM/RPR 0479.292.440 (Liège).

Listings
Euronext Brussels and Euronext Amsterdam: MDXH

Financial calendar
November 2, 2017 – Second business update (Q3 2017)

Financial year
The financial year starts on 1 January and ends on 31 December.

Statutory auditor
BDO Bedrijfsrevisoren / Réviseurs d'entreprises CVBA/SCRL
Da Vincilaan 9
1935 Zaventem
Belgium

Availability of the Interim Report
This document is available to the public free of charge and upon request:
MDxHealth SA - Investor Relations
CAP Business Center - Rue d'Abhooz, 31 – 4040 Herstal - Belgium
Tel: +32 4 364 20 70
E-mail: ir@mdxhealth.com

For informational purposes, an electronic version of the Interim Report 2016 is available on the website of MDxHealth at www.mdxhealth.com/investors/financials